PRTN3 and rheumatoid arthritis: These criteria combine clinical severity of the disease by enumerating affected joints with systemic inflammation and presence of RA-specific antibodies such as rheumatoid factor (RF) and anti-citrullinated peptides antibodies (ACPA) [1].